KAPA

Kairos Pharma, Ltd.
CAPPED RATING

Kairos Pharma, Ltd. (KAPA) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
B+
Factor Score 3.7 / 5.0
Growth
D-
Factor Score 1.0 / 5.0
Profitability
D
Factor Score 1.4 / 5.0
Momentum
F
Factor Score 0.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.1
EV / EBITDA 0.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -79.8%
Price Return 12M -92.2%
Catalyst Signal 0.00
Market Cap $1.7M
TTM Revenue N/A
Price / Sales N/A
ROE -114.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B+ (3.7) D- (1.0) D (1.4) F (0.4) C+ (2.6) D+ (1.8)
2026-11-05 A- (3.9) D- (1.0) D (1.5) F (0.4) C+ (2.7) C- (1.9)
2026-10-29 B+ (3.7) D- (1.0) D+ (1.7) F (0.6) C+ (2.7) C- (1.9)
2026-10-22 B+ (3.7) D- (1.0) D+ (1.7) F (0.5) C+ (2.6) C- (1.9)
2026-10-15 B+ (3.7) D- (1.0) D+ (1.7) F (0.7) C+ (2.6) C- (1.9)
Page 1 of 3